SavedAdd your journal

Journals / The European Research Journal / 2020 / Cilt: 6 - Sayı: 2

Hepatitis B seroprevalence in hematological oncology patients

Melda Türken
Şükran Köse
Cengiz Ceylan
Ayşe Özkan Acar
Hazal Albayrak
Eren Arkalı
Pages
87–91
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The obtained datas were evaluated bySPSS for Windows 15.00 statistical program.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today.
📊
Key Findings & Data:In our study, HBV seroprevalence was evaluatedretrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxisin patients with hematological malignancy.Methods: A total of 499 patients were included in the study.
💡
Conclusion & Impact:The obtained datas were evaluated bySPSS for Windows 15.00 statistical program.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factorssuch as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. areinvolved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluatedretrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxisin patients with hematological malignancy.Methods: A total of 499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBVDNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) withReal-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated bySPSS for Windows 15.00 statistical program. A value of p

🔖

Cite This Article

Türken, M., Köse, Ş., Ceylan, C., Acar, A. Ö., Albayrak, H., Arkalı, E. (2022). Hepatitis B seroprevalence in hematological oncology patients. The European Research Journal, Cilt: 6 - Sayı: 2, 87–91. https://ajindex.com/articles/597484

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Deveci Ö, Tekin A, Günbay SS, Kılıç D, Kaygusuz S, Ağalar C, et al. [Evaluation of HBsAg, anti-HCV, anti-HIV and VDRL test results in blood donors]. J Clin Exp Invest 2011
  2. [Article in Turkish] 2. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005
  3. 34 Suppl 1:S1-3. 3. Greeley RD, Semple S, Thompson ND, High P, Rudowski E, Handschur E, et al. Hepatitis B outbreak associated with a hematology-oncology office practice in New Jersey, 2009. Am J Infect Control 2001
  4. Utkan G, Azap A, Muallaoğlu S, Tokluoğlu S, Durnalı AG, Arslan ÜY, et al. [Hepatitis B and C seroprevalence in cancer patıents: a case control study]. Int J Hematol Oncol 2006
  5. [Article in Turkish] 5. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017
  6. Turkey Viral Hepatitis Diagnosis and Treatment Guide 2017. Available at: http://www.vhsd.org/tr/page/turkiye-viralhepatitliler-tani-ve-tedavi-kilavuzu-2-7.html May 2017. [Article in Turkish] 7. Uptodate 2017 Hepatitis B virus reactivation associated with immunosuppressive therapy. Available at: www.uptodate.com/contents/hepatitis-b-virus-reactivationassociated-with-immunosuppressive-therapy Dec 18, 2017. 8. Tosun S. [The changing viral hepatitis epidemiology in our country]. Ankem Derg 2013
  7. 27(suppl 2):128-34. 9. İnci A, Okay M, Güven D. [HBsAg, Anti-HBs, Anti-HCV and Anti-HIV seroprevalence of the patients applied to Artvin State Hospital]. Viral Hepatit Derg 2013
  8. [Article in Turkish] 10. Şardaş OS, Tekeli E, Koç H, Balık İ, Dağcı Ş, Ertural F. [The prevalence of the hepatitis B virus markers in the haematologıcongologıc patients who had frequently received transfusion]. Turkiye Klinikleri J Med Res 1990
  9. [Article in Turkish] 11. Sarı R, Özkan Hİ, Sevinç A, Aydoğdu İ. [Seropositivity of hepatitis B and hepatitis C viruses in blood and blood products in transfused and non-transfused patients with hematological malignancies]. Turgut Özal Tıp Merkezi Dergisi 2000
  10. [Article in Turkish] 12. Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr 2011
  11. Yalçıntaş Arslan Ü, Önder FO, Uncu D, Tokluoğlu S, Gök Durnalı A, Çelenkoğlu G, et al. [Hepatitis B and C Virüs Seroprevalance of the Patients vvith Non-Hodgkin’s Lymphoma: Single Center Expe